Theraclion: First German patients with thyroid nodules treated with Echopulse® in clinical routine

Regulatory News:

THERACLION (Paris:ALTHE) (Alternext, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy, announces today that for the first time, thyroid patients have been treated in Germany in clinical routine. Four patients with benign thyroid nodules have been treated with the Echopulse system in a practice located in Paderborn.

The patients were treated with Echopulse therapeutic ultrasound in a completely non-invasive way in the outpatient setting. No pre-medication, local or general anesthesia were administered and simple paracetamol or ibuprophene were proscribed to patients as needed.

More than 1.5 million Germans patients now covered by their insurance company

Theraclion also announces that three more insurers have joined the thyroid Echopulse integrated care contract increasing the number of insurance companies covering the thyroid treatment to 4. The first insurance company to join this contract was NOVITAS BKK. Novitas BKK is one of the most traditional insurers in Germany. Since the start of the contract in September, Novitas has now been joined by these three new companies: BKK RWE, SIEMAG BKK and Brandenburgische BKK.

Echopulse is currently approved in Europe for 2 indications: benign thyroid nodules and breast fibrodanomas, the most common form of benign nodules in the breast. The insurance contact for the latter was launched with the Marienhospital in Bottrop and the Continentale BKK at year end 2014. This contract now covers more than 1.5 million Germans and has in the meantime been joined by the BKK Schleswig-Holstein, BKK VBU, BKK Braun-Gillette, NOVITAS BKK, BKK RWE, SIEMAG BKK, Brandenburgische BKK and the HEK.

Echopulse reimbursement by German insurance companies:

"German insurers join the integrated care contract because they understand the benefits Echopulse provides to the healthcare system: as an ambulatory treatment, without general anesthesia, without incisions and the related infection risks, patients can return to their normal live almost immediately. Costs compared to surgery are lower and patients look for insurers that offer innovative, non-invasive treatments,” says Anja Kleber, VP Marketing and Market Access, Theraclion.

"With the Echopulse extending its reach to nonacademic settings for thyroid nodules, and the procedure being covered by additional public insurance companies more and more patients have access to the procedure,” concludes David Caumartin, CEO of Theraclion.

About Theraclion

Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound.

Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 30 people, 53 percent of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion’s website: www.theraclion.com.

Theraclion is listed on Alternext Paris
PEA-PME Eligible
Mnemonic: ALTHE - ISIN Code: FR0010120402

View source version on businesswire.com: http://www.businesswire.com/news/home/20151102006927/en/